查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103827

α-甘露醣儲積症市場：全球市場預測，2026-2032年

Alpha Mannosidosis Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，α-甘露醣儲積症市場規模將達到 13,0964 億美元，複合年成長率為 17.12%。

主要市場統計數據
基準年 2025 4.3299億美元
預計年份：2026年 5.0344億美元
預測年份 2032 130964億美元
複合年成長率 (%) 17.12%

α-甘露甘露醣儲積症執行摘要

α-甘露醣儲積症症是一種極為罕見的遺傳性溶小體儲積症，由α-甘露糖苷酶缺乏所引起，導致富含甘露糖的寡糖在多種組織中進行性累積。此病通常伴隨發育遲緩、智慧障礙、反覆性行為感染、骨骼異常、聽力障礙、運動功能障礙和進行性多器官功能障礙。由於其症狀常與其他代謝性疾病、免疫性疾病、神經系統疾病和整形外科疾病重疊，因此延遲診斷仍然是臨床實踐中的一大挑戰。

α-甘露醣儲積症。

α-甘露醣儲積症缺乏症的診療模式正經歷顯著的轉變，從基於症狀的識別轉向透過基因檢測進行診斷和終身協調管理。傳統上，許多患者只有在出現長期反覆性行為感染、聽力喪失、臉孔粗糙、骨骼併發症、學習障礙或進行性等症狀後才被確診。次世代定序、代謝檢測、尿寡糖分析和酵素活性測定等技術的廣泛應用，提高了臨床醫生在懷疑溶小體儲積症時（尤其是在出現不明原因神經發育障礙和多重器官症狀的兒童和成人患者中）的診斷準確性。

人工智慧的累積影響

人工智慧正開始對α-甘露醣儲積症缺乏症產生影響，其作用並非在於取代孤立的臨床任務，而是透過加速診斷、協調治療和生成證據來實現。當電子健康記錄記錄了反覆性行為感染、溶小體儲積症障礙、發育遲緩、骨骼觀察、步態障礙和代謝檢測結果異常等症狀時，人工智慧驅動的臨床決策支援系統可以幫助識別與溶酶體貯積症相符的模式。在基因組醫學領域，機器學習可以幫助確定MAN2B1相關疾病突變的優先級，但所有輸出結果仍需專家解讀、生化檢測確認和遺傳諮詢。

區域性對α-甘露甘露醣儲積症缺乏症現狀的關鍵見解

在亞太地區，隨著基因組醫學、兒童代謝疾病診療和罕見疾病政策的廣泛投資，人們對α-甘露醣儲積症的認知正在不斷提高。基於定序的診斷和專業轉診網路的使用正在擴展，尤其是在日本、韓國、中國、印度和澳洲。都市區之間的醫療資源取得仍然存在差異，因此，加強臨床醫生培訓、完善本地檢測基礎設施以及規範轉診流程至關重要。在北美，已建立的罕見疾病支持體系、基因檢測基礎設施、孤兒藥研發路徑和專業的代謝疾病中心為早期診斷和多學科管理提供了支持；然而，複雜的保險流程、門診就診的負擔以及確保持續治療仍然是重要的障礙。

α-甘露甘露醣儲積症缺乏症的照顧與取得的關鍵群體分析

在東協地區，α-甘露甘露醣儲積症酶缺乏症的診療受到多種醫療保健體系的影響，兒童醫療服務不斷擴展，主要都市區分子診斷的普及程度也在提高；然而，保險報銷和罕見疾病治療的可及性仍然存在差異。在海灣合作理事會（GCC）國家，基因組醫學投入的增加、全國範圍的篩檢舉措以及遺傳疾病項目的開展尤為值得關注，尤其是在常染色體隱性遺傳病方面，家族病史和近親結婚會增加診斷的可能性。歐盟為罕見疾病提供了相對成熟的政策環境，透過協調的法律規範、參考網路、患者登記系統和跨境合作，支持診斷、證據收集和獲得專科治療。

主要國家α-甘露醣儲積症缺乏症的趨勢

在美國，罕見疾病生態系統已相當完善，這得益於基因檢測、專門的代謝疾病中心、新生兒篩檢基礎設施以及孤兒藥獲取途徑的普及；然而，保險公司的核准和醫療協調可能會影響患者的就醫體驗。在加拿大，先進的專業技術和協調的公共醫療保健系統十分強大，但地理距離和省際差異可能會影響患者獲得診斷和先進治療的機會。在墨西哥和巴西，人們對罕見疾病的認知正在提高，法律體制也在不斷完善，主要都市區的診斷能力也在提升；然而，更廣泛的醫療服務取得仍然依賴轉診途徑和報銷機制。

為行業領導者提供的實用建議

業界領導者應優先考慮α-甘露甘露醣儲積症缺乏症的早期診斷，並支持臨床醫生了解多重器官預警訊號，包括發育遲緩、反覆性行為感染、聽力喪失、骨骼異常、步態障礙和進行性神經系統觀察。診斷流程應整合酶活性檢測、尿寡糖分析、MAN2B1基因檢測和家庭諮詢，以減少誤診並提高轉診至代謝專家的及時性。

調查方法

本篇關於α-甘露醣儲積症的執行摘要的調查方法是基於循證的二手研究、臨床指南迴顧、監管資訊、同行評審文獻分析以及對既定罕見疾病政策框架的整合。主要資訊來源包括生物醫學資料庫、孤兒藥文件、遺傳代謝性疾病相關參考文獻、公共衛生罕見疾病措施、基因檢測資源、臨床試驗註冊庫、患者登記出版物以及代謝疾病專家的共識資料。

結論

α-甘露醣儲積症缺乏症正從一種歷史上未被充分認知的溶小體儲積症，轉變為一種更具可干預性的罕見疾病領域，這得益於基因組診斷、專業的代謝護理、孤兒藥研發路徑、人工智慧驅動的數據智慧以及協作式患者支持。早期發現仍然是一項核心挑戰，因為診斷延遲會阻礙及時干預、生育計劃支持以及對進行性多器官併發症的適當管理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：α-甘露甘露醣儲積症症市場：依治療類型分類

  • 骨髓移植
  • 酵素替代療法

第8章：α-甘露甘露醣儲積症市場：依適應症類型分類

  • I型α-甘露甘露醣儲積症
  • II型α-甘露甘露醣儲積症
  • 第三型α-甘露甘露醣儲積症

第9章：α-甘露甘露醣儲積症市場：依診斷法分類

  • 酵素活性測定
  • 基因檢測
  • 產前診斷
  • 新生兒篩檢

第10章：α-甘露甘露醣儲積症市場：依最終用戶分類

  • 醫院
  • 專科診所

第11章：α-甘露甘露醣儲積症市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：α-甘露甘露醣儲積症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：α-甘露甘露醣儲積症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • Amicus Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • CHIESI Farmaceutici SpA
  • Eli Lilly and Company
  • JCR Pharmaceuticals Co., Ltd.
  • Kamada Ltd.
  • Orchard Therapeutics PLC
  • Pfizer, Inc.
  • Protalix Biotherapeutics
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-C002B1C99848

The Alpha Mannosidosis Market is projected to grow by USD 1,309.64 million at a CAGR of 17.12% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 432.99 million
Estimated Year [2026] USD 503.44 million
Forecast Year [2032] USD 1,309.64 million
CAGR (%) 17.12%

Alpha Mannosidosis Executive Summary

Alpha mannosidosis is an ultra-rare, inherited lysosomal storage disorder caused by deficient alpha-mannosidase enzyme activity, leading to progressive accumulation of mannose-rich oligosaccharides across multiple tissues. The condition is typically associated with developmental delay, intellectual disability, recurrent infections, skeletal abnormalities, hearing impairment, motor dysfunction, and gradual multisystem deterioration. Because symptoms often overlap with other metabolic, immunologic, neurologic, and orthopedic conditions, diagnostic delay remains a central challenge in clinical practice.

The Alpha Mannosidosis landscape is increasingly shaped by rare disease policy, newborn and early-life diagnostic initiatives, genomic testing adoption, enzyme replacement therapy access, hematopoietic stem cell transplantation considerations, multidisciplinary care models, and long-term patient registries. Search interest and clinical discourse are converging around high-value topics such as alpha mannosidosis diagnosis, lysosomal storage disorders, MAN2B1 gene mutation, enzyme replacement therapy, rare genetic disease treatment, pediatric metabolic disorders, and orphan drug access. The most important strategic priority is not volume expansion but earlier recognition, evidence-based referral, equitable access to specialized care, and improved longitudinal outcomes for patients and families.

Transformative Shifts in the Alpha Mannosidosis Landscape

The Alpha Mannosidosis landscape is undergoing a measurable transformation from symptom-led recognition toward genetics-enabled diagnosis and coordinated lifelong management. Historically, many patients were identified only after years of recurrent infections, hearing loss, coarse facial features, skeletal complications, learning difficulties, or progressive ataxia. Wider use of next-generation sequencing, metabolic testing, urinary oligosaccharide analysis, and enzyme activity assays is improving diagnostic precision, particularly when clinicians consider lysosomal storage disorders in children and adults with unexplained neurodevelopmental and multisystem symptoms.

Therapeutic decision-making is also evolving. Enzyme replacement therapy has strengthened the focus on treatable rare metabolic diseases, while hematopoietic stem cell transplantation continues to be discussed in selected pediatric contexts, particularly where neurological trajectory, age, donor availability, and risk-benefit considerations are carefully evaluated. The care model is shifting toward integrated teams involving metabolic specialists, neurologists, immunologists, audiologists, orthopedic experts, rehabilitation clinicians, genetic counselors, and psychosocial support providers. At the system level, orphan drug regulation, compassionate access pathways, rare disease centers of excellence, digital registries, and patient-reported outcome frameworks are reshaping evidence generation and care delivery.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence Alpha Mannosidosis through diagnostic acceleration, care coordination, and evidence generation rather than through stand-alone clinical replacement. AI-enabled clinical decision support can help flag patterns consistent with lysosomal storage disorders when electronic health records contain combinations of recurrent infections, hearing impairment, developmental delay, skeletal findings, gait disturbance, and abnormal metabolic results. In genomic medicine, machine learning can support variant prioritization for MAN2B1-related disease, although all outputs require expert interpretation, confirmatory biochemical testing, and genetic counseling.

AI can also strengthen rare disease research by harmonizing fragmented real-world datasets, extracting longitudinal signals from medical records, supporting natural history studies, and improving adverse event surveillance. In imaging and functional assessment, algorithmic tools may assist in tracking skeletal, neurologic, or mobility-related progression when validated against clinically meaningful endpoints. The cumulative impact is most valuable when AI improves earlier referral, reduces the diagnostic odyssey, enables standardized follow-up, and supports equitable access to expertise. Governance remains essential: data privacy, bias mitigation, transparent validation, clinician oversight, and patient consent are critical in any AI-enabled Alpha Mannosidosis workflow.

Key Regional Insights Across the Alpha Mannosidosis Landscape

In Asia-Pacific, Alpha Mannosidosis awareness is advancing alongside broader investment in genomic medicine, pediatric metabolic care, and rare disease policy, with Japan, South Korea, China, India, and Australia showing growing use of sequencing-based diagnosis and specialized referral networks. Access remains uneven across urban and rural settings, making clinician education, regional laboratory capacity, and referral standardization important priorities. North America benefits from established rare disease advocacy, genetic testing infrastructure, orphan therapy pathways, and metabolic specialty centers, supporting earlier diagnosis and multidisciplinary management, although insurance navigation, travel burden, and continuity of care remain practical barriers.

Latin America is characterized by expanding rare disease legislation, improving diagnostic capabilities, and increasing specialist engagement in Brazil and Mexico, yet access to confirmatory testing, treatment reimbursement, and coordinated long-term care can vary substantially. Europe has one of the most structured environments for Alpha Mannosidosis care, supported by cross-border rare disease collaboration, orphan medicinal product frameworks, newborn screening expertise in selected jurisdictions, and reference networks for inherited metabolic disorders. The Middle East is strengthening tertiary care, genomic screening initiatives, and consanguinity-related genetic disease awareness, particularly in Gulf countries, creating opportunities for earlier identification of autosomal recessive disorders. Across Africa, Alpha Mannosidosis remains underdiagnosed due to limited metabolic testing, constrained specialist availability, and low awareness; however, expanding genomics partnerships, newborn and child health programs, and regional centers of excellence are gradually improving rare disease visibility.

Key Group Insights for Alpha Mannosidosis Care and Access

Within ASEAN, Alpha Mannosidosis care is influenced by diverse health systems, growing pediatric specialty capacity, and increasing adoption of molecular diagnostics in major urban centers, while reimbursement and access to rare disease therapies remain inconsistent. The GCC is notable for rising investment in genomic medicine, national screening initiatives, and inherited disease programs, which are especially relevant for autosomal recessive conditions where family history and consanguinity can increase diagnostic suspicion. The European Union provides a comparatively mature policy environment for rare diseases, with coordinated regulatory frameworks, reference networks, registry development, and cross-border collaboration that support diagnosis, evidence generation, and specialized care access.

BRICS countries show strong strategic relevance because they combine large populations, expanding genomic infrastructure, and growing rare disease policy attention, yet variability in reimbursement, specialist distribution, and diagnostic pathways affects patient access. G7 countries generally have stronger clinical research ecosystems, regulatory clarity for orphan therapies, and broader availability of metabolic specialists, making them important hubs for clinical guidance, treatment access, and registry-based evidence. NATO countries overlap significantly with high-income health systems in North America and Europe, where rare disease preparedness, supply chain resilience, digital health infrastructure, and cross-institutional clinical collaboration can support continuity of Alpha Mannosidosis care during public health or geopolitical disruptions.

Key Country Insights in Alpha Mannosidosis

The United States has a well-developed rare disease ecosystem supported by genetic testing availability, metabolic centers, newborn screening infrastructure, and orphan therapy access pathways, though payer authorization and care coordination can affect patient experience. Canada offers strong specialist expertise and public health system coordination, but geographic distance and provincial differences can influence access to diagnostics and advanced therapies. Mexico and Brazil are strengthening rare disease recognition and legislative frameworks, with major urban centers offering improving diagnostic capacity while broader access remains dependent on referral pathways and reimbursement mechanisms.

In the United Kingdom, Alpha Mannosidosis care benefits from national rare disease planning, genomic medicine initiatives, and specialist metabolic services. Germany and France have advanced inherited metabolic disease networks, strong clinical expertise, and established orphan drug processes, while Italy and Spain support rare disease care through regional specialist centers and national policy frameworks. Russia has medical genetics and metabolic expertise concentrated in key centers, but access consistency can vary across regions. China is rapidly expanding rare disease policy, sequencing capacity, and specialist centers, creating stronger diagnostic pathways for lysosomal storage disorders. India has rising genomic testing adoption and pediatric metabolic expertise in major cities, but affordability and awareness remain central challenges. Japan and South Korea combine advanced diagnostics, specialist care, and structured regulatory environments for rare diseases. Australia benefits from genetic medicine services, metabolic clinics, newborn screening expertise, and telehealth-enabled specialist access, although distance and low disease prevalence make coordinated referral pathways important for continuity of care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier Alpha Mannosidosis diagnosis by supporting clinician education on multisystem red flags, including developmental delay, recurrent infections, hearing loss, skeletal abnormalities, gait disturbance, and progressive neurologic features. Diagnostic pathways should integrate enzyme activity testing, urinary oligosaccharide analysis, MAN2B1 genetic testing, and family counseling to reduce the diagnostic odyssey and improve timely referral to metabolic specialists.

Care delivery strategies should focus on multidisciplinary centers, standardized follow-up protocols, patient registries, real-world evidence generation, and patient-reported outcomes that reflect function, mobility, hearing, cognition, infection burden, caregiver impact, and quality of life. Stakeholders should improve equitable access by aligning reimbursement evidence with rare disease policy requirements, expanding telemedicine for remote patients, strengthening laboratory networks, and supporting transition planning from pediatric to adult care. AI initiatives should be deployed only when clinically validated, privacy-preserving, and integrated into expert-led workflows. The most actionable path forward is to connect diagnosis, treatment access, monitoring, and family support into a single coordinated rare disease care continuum.

Research Methodology

The research methodology for this Alpha Mannosidosis executive summary is grounded in evidence-based secondary research, clinical guideline review, regulatory intelligence, peer-reviewed literature analysis, and synthesis of recognized rare disease policy frameworks. Core source categories include biomedical databases, orphan medicinal product documentation, inherited metabolic disorder references, public health rare disease strategies, genetic testing resources, clinical trial registries, patient registry publications, and consensus materials from metabolic disease experts.

The analytical approach emphasizes verified qualitative evidence rather than market sizing, market share analysis, or forecasting. Data were evaluated for clinical relevance, source credibility, recency, consistency across jurisdictions, and applicability to Alpha Mannosidosis diagnosis, treatment, access, and care delivery. Regional, group, and country insights were developed by assessing healthcare infrastructure, rare disease policy maturity, genomic testing availability, specialist network development, reimbursement environment, and practical access barriers. Findings were synthesized into an SEO-optimized executive narrative designed to support strategic decision-making while avoiding unsupported claims and unverified commercial assumptions.

Conclusion

Alpha Mannosidosis is moving from a historically underrecognized lysosomal storage disorder toward a more actionable rare disease landscape shaped by genomic diagnosis, specialized metabolic care, orphan therapy pathways, AI-enabled data intelligence, and coordinated patient support. The central challenge remains early identification, as delayed diagnosis can limit timely intervention, family planning support, and appropriate management of progressive multisystem complications.

Across regions and health system groups, the strongest opportunities lie in expanding awareness, improving confirmatory testing access, building multidisciplinary referral networks, and generating robust real-world evidence. Countries with mature rare disease policies and advanced genetic medicine infrastructure are better positioned to deliver coordinated care, while emerging systems can accelerate progress through targeted education, laboratory partnerships, and regional centers of excellence. Sustained improvement in Alpha Mannosidosis outcomes will depend on aligning science, policy, clinical practice, and patient-centered support across the full care continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Alpha Mannosidosis Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Bone Marrow Transplantation
  • 7.3. Enzyme Replacement Therapy

8. Alpha Mannosidosis Market, by Indication Type

  • 8.1. Introduction
  • 8.2. Type I Alpha Mannosidosis
  • 8.3. Type II Alpha Mannosidosis
  • 8.4. Type III Alpha Mannosidosis

9. Alpha Mannosidosis Market, by Diagnosis Method

  • 9.1. Introduction
  • 9.2. Enzyme Assay
  • 9.3. Genetic Testing
  • 9.4. Prenatal Diagnosis
  • 9.5. Newborn Screening

10. Alpha Mannosidosis Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Alpha Mannosidosis Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Alpha Mannosidosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Alpha Mannosidosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abeona Therapeutics Inc.
  • 15.2. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • 15.3. Amicus Therapeutics, Inc.
  • 15.4. BioMarin Pharmaceutical Inc.
  • 15.5. CHIESI Farmaceutici S.p.A.
  • 15.6. Eli Lilly and Company
  • 15.7. JCR Pharmaceuticals Co., Ltd.
  • 15.8. Kamada Ltd.
  • 15.9. Orchard Therapeutics PLC
  • 15.10. Pfizer, Inc.
  • 15.11. Protalix Biotherapeutics
  • 15.12. Quest Diagnostics Incorporated
  • 15.13. Sanofi S.A.
  • 15.14. Sarepta Therapeutics, Inc.
  • 15.15. Takeda Pharmaceutical Company Limited
  • 15.16. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALPHA MANNOSIDOSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ALPHA MANNOSIDOSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ALPHA MANNOSIDOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BONE MARROW TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BONE MARROW TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BONE MARROW TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE I ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TYPE I ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE I ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TYPE II ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE II ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TYPE II ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE III ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TYPE III ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE III ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZYME ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZYME ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZYME ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRENATAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRENATAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRENATAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 81. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 96. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 108. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 117. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 118. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 147. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 162. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 163. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2032 (USD MILLION)
  • TABLE 177. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 179. GLOBAL ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025